» Go to news main
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Posted by Angie Kinsman on
June 30, 2022
in
Nuclear Medicine
Dr. Steven Burrell has published a new article in Le Patient Magazine!
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Steven Burrell, MD, FRCPC Head of Nuclear Medicine QEII Health Sciences Centre
"When cancer has spread within the body the 2 main pillars of treatment are drugs such as chemotherapy which are administered internally and distribute throughout the body, and radiation which delivers tumour-destroying radiation from outside the body. However there is another approach..." Read more.
Recent News
- Program Administrator Award of Excellence
- Dr. Siân Iles interviewed on CBC's Information Morning
- Dr. Steven Beyea and Dr. Adela Cora featured in the latest Beyond Research podcast from ResearchNS
- Dr. Andreu Costa recognized as a CARJ 2023 Outstanding Reviewer!
- Department Faculty awarded EJNMMI Physics Best Paper 2023
- Dr. Hodgson wins world entrepreneurship contest
- Congratulations to the 2023 David Fraser Radiology Research Foundation Summer Studentship recipients!
- Congratulations, Dr. Brewer! The Charles Lo Prize in Radiology Research
Comments
All comments require a name and email address. You may also choose to log-in using your preferred social network or register with Disqus, the software we use for our commenting system. Join the conversation, but keep it clean, stay on the topic and be brief.
Read comments policy.
comments powered by Disqus